An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone

Soo Jeong NamDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; ;The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea;

Sehui KimDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; ;The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea;

Jin Ho PaikDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea;

Tae Min KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

Dae Seog HeoDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

Chul Woo KimDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; ;The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea;

Yoon Kyung JeonDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; ;The Tumor Immunity Medical Research Center, Cancer Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea; Correspondence[email protected]

show all

An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone

Supplementary tables

Supplementary Figure S3.

Supplementary Figure S2.

Supplementary Figure S1.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone

Supplementary tables

Supplementary Figure S3.

Supplementary Figure S2.

Supplementary Figure S1.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date